Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QM101
- Development stage
- Unknown
- Lead developer
- 北京奇迈永华
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
QM101 is an autologous, feeder-free, and serum-free natural killer (NK) cell therapy product developed by Gene MiNK Biotechnology (Beijing Qimai Yonghua Biotechnology) and Qimai Guoji (Jilin) Biotechnology for the treatment of advanced solid tumors. Manufactured using a proprietary expansion platform, QM101 consists of highly pure (>99%) NK cells with potent cytotoxic activity. The therapy is administered via intravenous infusion to mobilize the patient's immune system to target and destroy solid tumor cells.
- Other names
- QM-101 Cell InjectionQM101 Cell InjectionQM 101 Cell InjectionQM101自体NK细胞注射液
Beyond the preview
Go deeper on QM101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QM101.